On this page
Quick Reference
Overview and Recommendations
Background
- •Tobacco use is the leading preventable cause of death globally, responsible for over 480,000 US deaths annually. Cessation interventions are among the most cost-effective clinical preventive services, with the USPSTF issuing a Grade A recommendation for universal screening and intervention.
- •Nicotine dependence is driven by dopamine release in the mesolimbic pathway, reinforced by psychosocial factors such as stress coping and social bonding. This creates a self-reinforcing cycle that heightens cravings for other substances and complicates sustained abstinence.
- •The three main intervention categories are behavioral counseling (individual, group, telephone quitline), pharmacotherapy (nicotine replacement therapy [NRT], varenicline, bupropion SR), and their combination. Combined therapy yields the highest abstinence rates, with a pooled relative risk of 1.83 compared to minimal support.
- •Certain populations bear a disproportionate burden: people with HIV are 2-3 times more likely to smoke, individuals with schizophrenia have a 10-year shorter life expectancy partly due to smoking, and low-SES smokers have lower quit rates. Tailored interventions are critical.
- •Evidence-based interventions include the 5A's framework (Ask, Advise, Assess, Assist, Arrange) and the Ottawa Model, which integrates hospital-initiated counseling, NRT, and telephone follow-up to reduce readmissions and mortality.
Evaluation
- •Suspect tobacco use disorder in any patient using any tobacco product. Screen universally at every clinical encounter with a single question: "Do you use any tobacco products?"
- •Ask about the type of tobacco (cigarettes, smokeless, e-cigarettes, hookah, cigars), quantity (cigarettes per day), duration of use, and time to first cigarette after waking, the single strongest indicator of nicotine dependence.
- •Inquire about past quit attempts: what methods were tried, why they failed, and how long abstinence lasted. Withdrawal symptoms (irritability, craving, anxiety, difficulty concentrating) typically begin within 24 hours of cessation.
- •Examine for physical signs of chronic tobacco use: tobacco odor, nicotine staining of fingers, chronic cough, and oral leukoplakia (especially with smokeless tobacco).
- •For patients with comorbid HIV, tuberculosis, or psychotic disorders, recognize that tobacco use is more prevalent and cessation is especially urgent due to higher mortality.
- •The gold-standard diagnostic assessment is the clinical interview using DSM-5 criteria for tobacco use disorder. For rapid quantification, use the Fagerström Test for Nicotine Dependence (FTND), a 6-item questionnaire scored 0-10; a score ≥6 indicates high dependence.
- •An alternative rapid screen is the Heaviness of Smoking Index (HSI), using time to first cigarette and cigarettes per day; a score ≥4 indicates high dependence.
- •Assess readiness to quit using the Readiness to Change Ruler (0-10) or the Stages of Change model. A score of ≥7 suggests the patient is ready to make a quit attempt within 30 days.
- •Biochemical verification (exhaled carbon monoxide <10 ppm or urine/serum cotinine) is not required for routine diagnosis but is useful in research, pregnancy, or when misreporting is suspected.
- •Apply the 5A's framework systematically: Ask about use, Advise to quit, Assess willingness, Assist with pharmacotherapy and counseling, and Arrange follow-up. National data show that 88% of smokers are asked but only 18% have follow-up arranged, the largest gap.
- •For patients with high dependence (FTND ≥6) or comorbid mental illness, plan for combination pharmacotherapy (e.g., NRT patch plus gum) and referral to intensive behavioral support.
Management
- •At every acute care encounter, deliver a brief intervention (≤3 minutes): advise the patient to quit, assess readiness, and offer assistance. Even 30 seconds of advice increases the likelihood of a quit attempt (NNT=6).
- •For nonpregnant adults ready to quit, initiate first-line pharmacotherapy: varenicline (start 0.5 mg daily for 3 days, then 0.5 mg BID for 4 days, then 1 mg BID for 12 weeks); bupropion SR (150 mg daily for 3 days, then 150 mg BID for 7-12 weeks); or NRT (patch, gum, lozenge, inhaler, or nasal spray per label).
- •For patients with high nicotine dependence (FTND ≥6), use combination NRT, a transdermal patch (e.g., 21 mg/24 hours) plus a short-acting form (gum 2-4 mg hourly or lozenge), to improve quit rates.
- •Combine pharmacotherapy with behavioral counseling: the pooled relative risk for combined therapy is 1.83 compared to minimal support, significantly better than either alone.
- •For low-SES smokers, implement proactive outreach with telephone counseling, free NRT for 6 weeks, and community referrals; this achieves a 17.8% quit rate versus 8.1% (NNT=10).
- •For patients with schizophrenia or serious mental illness, use a personalized intervention package (counseling plus pharmacotherapy) to achieve 28% abstinence at 6 months (NNT=6).
- •In adolescents (<20 years), group counseling is effective (RR 1.35); pharmacotherapy and individual counseling have insufficient evidence and should not be used as first-line.
- •In pregnant women, behavioral counseling is the first-line intervention; do not initiate pharmacotherapy due to insufficient evidence of benefit and unknown harms. Refer to specialized prenatal cessation support.
- •For perioperative patients, offer a cessation intervention at least 4 weeks before surgery to reduce postoperative complications; NNT=7 for abstinence at the time of surgery.
- •Extend pharmacotherapy beyond 12 weeks for patients at high risk of relapse; the USPSTF supports use up to 6 months.
- •Refer all patients to a state quitline (1-800-QUIT-NOW) for ongoing telephone counseling; this is accepted by >90% of patients and increases abstinence.
- •The Ottawa Model (hospital-initiated counseling, NRT, and telephone follow-up) reduces all-cause 30-day readmission (ARR 6.1%, NNT=17) and 1-year mortality (ARR 6.0%, NNT=17).
- •What NOT to do: do not rely solely on written materials; do not assume patients are uninterested; do not recommend e-cigarettes for cessation (insufficient evidence).
- •Monitor for adverse effects of pharmacotherapy: varenicline may cause nausea, insomnia, and rare neuropsychiatric events; bupropion may lower seizure threshold; NRT may cause local skin reactions or oral irritation.
- •For patients with multiple failed quit attempts or co-occurring substance use disorders, refer to a tobacco treatment specialist or addiction medicine program.
Board Review — High Yield
- •Fagerström Test for Nicotine Dependence (FTND), A 6-item score (0-10); ≥6 indicates high dependence requiring combination pharmacotherapy.
- •The 5A's, Ask, Advise, Assess, Assist, Arrange; only 18% of smokers receive the Arrange step.
- •Varenicline, Pooled RR 2.24 for abstinence at 6 months vs placebo; start 0.5 mg daily, titrate to 1 mg BID.
- •Proactive outreach, Telephone counseling + free NRT + community referrals yields NNT=10 in low-SES smokers.
- •Perioperative cessation, NNT=7 for abstinence at surgery, reducing postoperative complications.
- •Ottawa Model, Hospital-initiated counseling + NRT + follow-up reduces 30-day readmission (NNT=17) and 1-year mortality (NNT=17).
- •Pregnancy, Behavioral counseling is first-line; pharmacotherapy has insufficient evidence.
- •Adolescents, Group counseling effective (RR 1.35); pharmacotherapy not proven.
- •Schizophrenia, Personalized intervention package achieves 28% abstinence at 6 months (NNT=6).
- •Combined therapy, Pharmacotherapy + behavioral support: RR 1.83 vs minimal support.
Deep Dive — Evidence Details
Definition, Classification and Nomenclature
- ▸Combined behavioral + pharmacotherapy yields highest quit rates.
- ▸Brief interventions (e.g., 3-5 min) significantly increase abstinence.
Tobacco cessation interventions are evidence-based practices to help individuals discontinue all forms of tobacco use, including behavioral counseling, pharmacotherapy, and their combination, delivered in clinical and community settings. Also called smoking cessation, tobacco treatment, or nicotine addiction treatment. Interventions are classified by modality and intensity: behavioral (counseling, motivational interviewing, quitline support), pharmacotherapy (FDA-approved medications: , , [NRT] patch, gum, lozenge, inhaler, nasal spray), and combined (behavioral plus pharmacotherapy). Combined therapy yields highest abstinence rates [2]A1a[4]A1a. Even brief interventions by oral health professionals increase abstinence by 71% (OR 1.71) [1]A1a. Interventions are effective across diverse populations, including dental patients, young people, and those with substance use disorders [2]A1a[3]A1a[4]A1a. Pearl: Interventions are effective across diverse populations, including dental patients, young people, and those with substance use disorders, as supported by Cochrane reviews [2]A1a[3]A1a[4]A1a.
| Intervention Type | Key Features | Examples |
|---|---|---|
| Behavioral | Counseling (individual, group, telephone, text), motivational interviewing, quitline support, contingency management | Brief advice (3-5 minutes), intensive counseling (≥4 sessions), (NRT) behavioral support programs |
| Pharmacotherapy | FDA-approved medications that reduce withdrawal and cravings; includes NRT and non-NRT agents | , , NRT (patch, gum, lozenge, inhaler, nasal spray) |
| Combined Behavioral + Pharmacotherapy | Integration of counseling with medication for synergistic effect | Behavioral support plus NRT or varenicline; often delivered in specialized clinics or pharmacist-led programs [6]C4 |
Pathophysiology and Mechanism
- ▸Nicotine reinforces use via dopamine; psychosocial factors complicate cessation.
- ▸Integrated interventions (pharmacotherapy + behavioral) are essential.
Nicotine drives dependence through dopamine release in the mesolimbic pathway, while psychosocial factors reinforce behavior. In populations with substance use disorders (SUDs), tobacco serves as a coping mechanism for stress, social bonding, and identity, especially for women with intersecting marginalized identities [7]D5[8]D5. Barriers include withdrawal symptoms (irritability, craving, anxiety) and psychosocial functions. A reinforcement cycle exists: tobacco use heightens cravings for other substances, increasing use of both [7]D5. Effective interventions must address both pharmacological addiction and psychosocial drivers, integrating NRT with behavioral counseling and social support [7]D5[8]D5. Tailoring to gendered experiences, e.g., non-stigmatizing counseling, may improve outcomes [8]D5. Pearl: Tobacco use is maintained by a self-reinforcing cycle of neurobiological addiction and psychosocial coping; effective cessation requires addressing both the withdrawal symptoms and the social and emotional functions of smoking.
Epidemiology, Etiology and Risk Factors
- ▸HIV, schizophrenia, TB, and low SES are major risk factors for continued tobacco use.
- ▸Targeted interventions in high-risk groups can double quit rates.
Tobacco use is concentrated among disadvantaged groups. People living with HIV are 2-3 times more likely to smoke [9]A1b. Persons with smoke more and have twice the mortality rate, with 10-year lower life expectancy [10]A1b. In India, 28.6% of adults use tobacco [17]B2a; among cancer patients, 74% continue use after diagnosis [17]B2a. Risk factors include HIV (RR 2-3), schizophrenia (increased prevalence), tuberculosis, low socioeconomic status, young age (15-26% prevalence) [3]A1a, and dual waterpipe/cigarette use (50% in PLWH in Viet Nam) [9]A1b. Interventions with motivational enhancement increase quit rates by 60% (RR 1.60) in young people [12]A1a. In military populations, interventions yield short-term OR 2.03 and long-term OR 1.53 [16]A1a. Pearl: When assessing a patient's risk for tobacco-related harm, ask about comorbid HIV, mental illness, or TB, these conditions more than double the likelihood of ongoing tobacco use and warrant targeted cessation interventions.
| Risk Factor | Odds Ratio / Relative Risk | Evidence Level |
|---|---|---|
| HIV infection | RR 2-3 (two to three times more likely to smoke) [9]A1b | 1b (RCT) |
| Schizophrenia and related psychotic disorders | Increased prevalence (smoke more) [10]A1b | 1b (experimental study) |
| Tuberculosis | Substantial evidence of association [11]B2b | 2b (quasi-experimental) |
| Low socioeconomic status | Heavy social gradient [14]D5 | 5 (cohort protocol) |
| Young age (<20 years) | Prevalence 15-26% [3]A1a | 1a (systematic review) |
| Dual waterpipe and cigarette use | 50% of PLWH in Viet Nam report dual use [9]A1b | 1b (RCT) |
| Continued tobacco use after cancer diagnosis | Pooled prevalence 74% [17]B2a | 2a (systematic review) |
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Should all tobacco users be screened for HIV? | No, only if clinical suspicion exists (CDC) | Yes, given high prevalence in PLWH (WHO) | Weak | Screen for tobacco in all HIV clinics; consider HIV testing in high-prevalence tobacco users |
Clinical Presentation
- ▸Psychosis patients have higher dependence and lower quit rates.
- ▸Brief interventions are effective but underutilized in acute settings.
Tobacco use disorder presents with varying dependence severity, motivation, and comorbidity. Among US adults with psychosis, past-month any tobacco use is 41.3% vs 27.7% in those without (adjusted RR 1.49) [18]C4. Dual cigarette/e-cigarette use is 13.5% vs 10.1% [18]C4. Hispanic border smokers are typically light smokers with low dependence and many quit attempts [21]C4. AIAN communities: 92% aware of risks, but only 29% knew of pharmacogenomics [22]C4. Dependence severity is higher in psychosis (PATH score 54.6 vs 49.5) [18]C4. Only 1 in 3 patients with received medication assistance from providers [20]C4. Brief interventions (1 min) increase quit attempt rate threefold but are inconsistently delivered [19]C4. Red flags: patients with psychosis underestimating lung cancer risk ( >50% believed low risk despite meeting screening criteria) [20]C4. Pearl: When a patient with psychosis or a heavy smoking history expresses low concern about lung cancer risk, probe for prior cessation attempts and explicitly offer pharmacotherapy, the gap between perceived risk and actual risk is a direct call to action, not a reassurance.
| Population | Key Clinical Features | Prevalence of Tobacco Use | Cessation Support |
|---|---|---|---|
| Adults with psychosis | Higher dependence, dual/poly-use, lower quit rates [18]C4 | 41.3% past-month any tobacco | < 33% received medication assistance [20]C4 |
| Hispanic (border region) | Light smokers, low dependence, many past quit attempts, limited cessation aid use [21]C4 | Varies; sample predominately male | Few used formal aids |
| AIAN community | High awareness of tobacco risks, but low pharmacogenomics literacy; distrust of research [22]C4 | 92% aware of risks, 76% see it as problem | 68% view pharmacogenomics as beneficial; 64% want tribal involvement |
Diagnosis and Workup
- ▸FTND score ≥6 guides combination pharmacotherapy.
- ▸Assess readiness to quit at every visit.
Assess tobacco use type, quantity (cigarettes/day), duration, time to first cigarette (strongest dependence indicator), past quit attempts, withdrawal symptoms. Physical exam: tobacco odor, nicotine staining, chronic cough, oral lesions. Gold standard: DSM-5 criteria for tobacco use disorder. The Fagerström Test for Nicotine Dependence (FTND) is the most validated tool (6 items, score 0-10; ≥6 = high dependence). The single question "How soon after waking?" (≤30 minutes = high dependence) is a rapid screen [25]B2b. The Heaviness of Smoking Index (HSI) (2 items) is brief for busy clinics. Biochemical verification not required routinely but useful in research or pregnancy; exhaled CO <10 ppm indicates non-smoker, cotinine (urine/saliva/serum) is more sensitive. Diagnostic algorithm: 1) Screen every encounter: "Do you use any tobacco?" 2) Assess dependence with FTND/HSI. 3) Assess readiness to quit (Readiness to Change Ruler, Stages of Change). 4) Document plan [25]B2b. Pearl: The single question "Do you smoke?" has high sensitivity; however, assessing dependence severity with the FTND and motivation with the Readiness to Change Ruler doubles the likelihood of selecting an effective cessation strategy.
| Assessment Tool | Purpose | Items | Scoring | Clinical Use |
|---|---|---|---|---|
| FTND | Quantify nicotine dependence | 6 items | 0-10; ≥6 = high dependence | Guides pharmacotherapy intensity |
| Heaviness of Smoking Index (HSI) | Rapid dependence screen | 2 items | 0-6; ≥4 = high dependence | Brief enough for busy clinics |
| Readiness to Change Ruler | Assess motivation to quit | 1 item (0-10 scale) | 0-10; ≥7 = ready to make a quit attempt | Informs counseling approach |
Severity, Staging and Risk Stratification
- ▸FTND ≥6 plus mental illness warrants intensive intervention.
- ▸Respiratory symptoms are strong motivators for quitting.
Stratify by nicotine dependence severity (FTND/HSI), comorbid risk factors, and readiness to change. Higher FTND scores predict greater difficulty quitting and need for combination therapy (NRT + ). High-risk populations: homelessness (high prevalence, barriers to quitting) [5]A1a, disability (veterans: 2× odds of cigarette use; higher poly-tobacco use RRR 1.74) [37]C4, (OR 1.33-2.35) [36]C4, tuberculosis (smoking increases TB risk 2-2.5×) [33]A1a. Respiratory symptoms motivate quitting: frequent phlegm (OR 2.10), cough (OR 1.74), wheeze (OR 1.73) in COPD patients [38]C4. Practical approach: (1) assess dependence, (2) ask readiness to quit in 30 days, (3) identify high-risk comorbidities, (4) for FTND ≥6 or any high-risk comorbidity, offer combination pharmacotherapy and refer to intensive behavioral counseling. Pearl: The combination of high nicotine dependence (FTND ≥6) and a comorbid mental health condition identifies a subgroup that benefits most from intensive behavioral counseling plus combination pharmacotherapy; these patients should be referred to specialized cessation services.
| Risk Factor | Association with Tobacco Use | Clinical Implication |
|---|---|---|
| Homelessness | High prevalence; substantial barriers to quitting [5]A1a | Provide low-barrier access to NRT and contingency management |
| Disability (veterans) | Graded association: significant functional difficulties → 2× odds of cigarette use; higher poly-tobacco use (RRR 1.74 vs non-use) [37]C4 | Assess functional limitations; adapt cessation materials |
| Postpartum depression | Tobacco associated with all severity levels of PPD (OR 1.33-2.35) [36]C4 | Integrate cessation into perinatal mental health care |
| Tuberculosis | Smoking increases TB risk 2-2.5×; cessation may improve treatment outcomes [33]A1a | Offer cessation at TB diagnosis; no RCT evidence yet |
Acute Management
- ▸Brief intervention (≤3 min) in acute care reduces readmission and mortality.
- ▸NRT initiation and quitline referral are key components.
In acute care settings (ED, inpatient psychiatry, hospital), use the 5 As framework. Step 1: Ask and advise - even one sentence increases quit attempt threefold [19]C4. Step 2: Assess readiness and deliver brief intervention (≤3 minutes) - 30-second intervention increased help-seeking from 44% to 61% (NNT=6) [40]A1b. Step 3: Offer first-line pharmacotherapy, NRT (patch, gum, lozenge) - initiate during visit. The INITIATE trial provides "Quit Card" worth $300 for NRT [34]D5. Step 4: Refer to quitline - >80% of ED providers use National Toll-Free Quitline [39]C4. Step 5: Document and transition to long-term care. The Ottawa Model (counseling + NRT + follow-up) reduced all-cause readmissions at 30 days from 13.3% to 7.1% (ARR 6.1%, NNT=17) and 1-year mortality from 11.4% to 5.4% (ARR 6.0%, NNT=17) [44]B2b. Do not rely solely on written materials; brief interactive counseling is essential. Pearl: Initiate a brief cessation intervention (≤3 minutes) during any acute care encounter; this can reduce 30-day readmission by 6% (NNT=17) and 1-year mortality by 6% (NNT=17) [44]B2b.
| Intervention Component | Description | Key Evidence | Outcome (if reported) |
|---|---|---|---|
| Brief counseling (≤3 min) | Positive tone, education, encouragement | [39]C4 provider preference; [40]A1b 30-sec intervention | 61% vs 44% sought help (NNT=6) [40]A1b |
| Motivational interviewing | Patient-centered, elicits change talk | Two studies with significant abstinence [42]D5 | Not quantified in abstract |
| Quitline referral | Provision of phone number or fax referral | [39]C4 used by 84% providers; [15]C4 2 A's + Quitline | >90% acceptability [15]C4 |
| NRT (patch, gum, lozenge) | Offered per label; no dose data in cited abstracts | [34]D5 Quit Card; [44]B2b Ottawa Model | Reduced readmission and mortality [44]B2b |
| Hospital-initiated program (Ottawa Model) | Counseling + NRT + follow-up | [44]B2b cohort study | 30-d readmission ARR 6.1% (NNT=17); 1-yr mortality ARR 6.0% (NNT=17) |
Long-term and Definitive Management
- ▸Varenicline is most effective, followed by bupropion and NRT.
- ▸Combined therapy is superior to either alone.
USPSTF Grade A recommends asking all adults about tobacco use, advising cessation, and providing behavioral interventions and FDA-approved pharmacotherapy [45]A1c. A 2021 meta-analysis found varenicline most effective (pooled RR 2.24), followed by bupropion (RR 1.64) and NRT (RR 1.55) [46]A1a. Combined pharmacotherapy + behavioral support yields RR 1.83 [46]A1a. A pragmatic trial of chatbot (Dejal@bot) showed 26% vs 18.8% abstinence (OR 1.52, NNT=14) [53]A1b. Proactive outreach for low-SES smokers: telephone counseling + free NRT for 6 weeks gave 17.8% vs 8.1% (OR 2.5, NNT=10) [47]A1b. Combination NRT (patch + gum) is recommended for high dependence. For patients who fail first-line, consider switching or adding another agent. Extend pharmacotherapy up to 6 months for high-risk patients [45]A1c. Automated IVR calls post-discharge + free medication showed higher odds of abstinence (OR 1.49 per call) [25]B2b. For young people, group counseling effective (RR 1.35) but pharmacotherapy not [54]A1a. For pregnant women, only behavioral interventions recommended [45]A1c. Pearl: Initiate pharmacotherapy (varenicline, bupropion, or NRT) and behavioral support together for the highest quit rates; for adolescents, pregnant women, and e-cigarette users, the evidence base is weaker, and behavioral interventions should be the cornerstone [45]A1c[46]A1a[54]A1a.
| Intervention | Indication | Pooled RR (95% CI) vs placebo/minimal support | Key trial example | Evidence level |
|---|---|---|---|---|
| Varenicline | First-line for nonpregnant adults | 2.24 (2.06-2.43) [46]A1a | , | 1a (meta-analysis) |
| Bupropion SR | First-line | 1.64 (1.52-1.77) [46]A1a | , | 1a |
| NRT (any form) | First-line | 1.55 (1.49-1.61) [46]A1a | Proactive outreach trial: NNT=10 [47]A1b | 1a |
| Behavioral counseling | All patients | 1.76 (1.58-1.96) clinician advice [46]A1a | Chatbot trial: NNT=14 [53]A1b | 1a |
| Combined pharmacotherapy + behavioral | First-line for nonpregnant adults | 1.83 (1.68-1.98) [46]A1a | , | 1a |
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Should e-cigarettes be recommended for cessation? | USPSTF (2021), evidence insufficient; balance of benefits and harms cannot be determined [45]A1c | Cochrane reviews, inconsistent findings; no higher rates of serious adverse events, but insufficient evidence for efficacy [46]A1a | Moderate | Do not recommend e-cigarettes as first-line therapy; advise patients that evidence is lacking [45]A1c |
| Pharmacotherapy in pregnancy | USPSTF, insufficient evidence; recommend only behavioral interventions [45]A1c | NICE (UK), may consider NRT after discussion of risks and benefits (not in provided references, but standard) | Strong | In pregnant patients, use behavioral interventions; if pharmacotherapy is considered, involve specialist and discuss uncertainty [45]A1c |
| Pharmacotherapy for adolescents | USPSTF, no specific recommendation; extrapolates adult evidence | Cochrane, no clear evidence of benefit for NRT or bupropion in adolescents [54]A1a | Moderate | In adolescents, emphasize group counseling; avoid pharmacotherapy unless under specialist guidance [54]A1a |
History and Evolution of Treatment
- ▸Proactive outreach to low-SES smokers yields NNT=10.
- ▸Combined therapy remains the most effective strategy.
The 2000 U.S. Public Health Service guideline established tobacco dependence as a chronic condition warranting repeated treatment, with dose-response counseling intensity [61]A1c. USPSTF reaffirmed Grade A in 2009 and 2021, recommending behavioral interventions and FDA-approved pharmacotherapy for nonpregnant adults, and pregnancy-tailored counseling for pregnant women [45]A1c[60]A1c. Landmark trials: Haas et al. (2015) proactive outreach for low-SES smokers: quit rate 17.8% vs 8.1% (OR 2.5, NNT=10) [47]A1b. Rigotti et al. (2017) IVR plus medication post-discharge: OR 1.49 per call [25]B2b. Olano-Espinosa et al. (2022) chatbot: 26% vs 18.8% abstinence (OR 1.52) [53]A1b. Wang et al. (2024) WeChat training improved provider utilization [51]A1b. For schizophrenia, Rajalu et al. (2023) personalized intervention: 28% vs 10.8% abstinence [10]A1b. For people with HIV, Elf et al. (2024) added NRT to counseling: 15% vs 10% (aOR 1.47, not significant) [26]A1b. Pearl: The evolution of tobacco cessation interventions demonstrates that the most effective strategies combine pharmacotherapy with behavioral support, and that proactive outreach to disadvantaged populations can substantially reduce disparities (NNT = 10 for proactive counseling + NRT in low-SES smokers [47]A1b).
Generalist Reasoning under Diagnostic Uncertainty, Point-of-Care Scores & Referral Thresholds
- ▸Only 17.5% of smokers receive arranged follow-up.
- ▸Brief intervention + quitline referral is effective in ED.
The 5A's (Ask, Advise, Assess, Assist, Arrange) are the standard. National data: 87.9% asked, 65.8% advised, 42.6% assessed, 78.2% assisted (if willing), but only 17.5% arranged follow-up [65]C4. The steep drop-off is the diagnostic gap. A simple question "Are you willing to try to quit within 30 days?" stratifies readiness. For those ready, offer pharmacotherapy or referral. Referral thresholds: patient ready to quit but needs pharmacotherapy (generalist can prescribe NRT or varenicline; if unwilling, refer to quitline). Multiple failed attempts or psychiatric comorbidity: refer to specialist. In ED, brief intervention with quitline referral is effective (used by 84% providers) [39]C4. Two studies showing significant effects used motivational interviewing [42]D5. Patient satisfaction >90% [42]D5. The 5A's framework serves as both diagnostic and triage tool. Pearl: The 5A's drop from 88% (Ask) to 18% (Arrange): the generalist who completes all five steps, especially the last two, will close the gap between identification and effective treatment. If uncertain about the patient's readiness, ask once; then act on the answer.
| 5A Component | % of Smokers Receiving (n=16,542) | Gap |
|---|---|---|
| Ask | 87.9% | 12% missed |
| Advise | 65.8% | 22% drop from Ask |
| Assess | 42.6% | 23% drop from Advise |
| Assist (if willing) | 78.2% | , |
| Arrange follow-up | 17.5% | 61% drop from Assist |
| Data from [65]C4 |
Complications
- ▸Peri-operative cessation interventions have NNT=7 for abstinence at surgery.
- ▸Smoking causes 480,000 deaths/year in US.
Peri-operative tobacco cessation interventions reduce postoperative complications. A meta-analysis of 38 RCTs found that peri-operative interventions increased abstinence at surgery (RR 1.48, NNT=7) and at 12 months (RR 1.62, NNT=9) [66]A1a. Complications prevented include wound infections, pulmonary complications, and cardiovascular events. In pregnancy, tobacco use increases miscarriage, congenital anomalies, SIDS, and impaired lung function [45]A1c. USPSTF recommends behavioral interventions for pregnant women (substantial net benefit); evidence on pharmacotherapy is insufficient [45]A1c. Smoking is a leading cause of preventable death (480,000 deaths/year in US) [45]A1c. Cessation reduces risk of cardiovascular disease, COPD, lung cancer over time. Pearl: For surgical patients, the peri-operative window is uniquely effective: offering a cessation intervention yields an NNT of 7 for abstinence at the time of surgery, directly reducing postoperative complications [66]A1a.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Postoperative complications (wound infection, pulmonary, cardiovascular) | Substantially increased risk in smokers (RR not reported in included studies) | Peri-operative tobacco cessation interventions; NNT 7 for abstinence at surgery [66]A1a | Standard peri-operative care; early recognition and treatment of infections, respiratory support, and cardiovascular monitoring |
| Adverse pregnancy outcomes (miscarriage, congenital anomalies, SIDS, impaired lung function) | 7.2% of pregnant US women smoked in 2016 [45]A1c | Behavioral interventions for cessation; pharmacotherapy evidence insufficient [45]A1c | Obstetric monitoring; neonatal care as indicated |
| Cardiovascular disease, lung cancer, COPD | Leading cause of preventable death, 480,000 deaths/year [45]A1c | Sustained tobacco cessation; FDA-approved pharmacotherapy with behavioral support [45]A1c | Standard disease-specific management; screening for early detection |
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Should e-cigarettes be recommended for cessation? | USPSTF: Insufficient evidence to recommend; balance of benefits and harms cannot be determined [45]A1c | Some clinicians advocate as harm reduction, but no RCTs support efficacy | Grade I (insufficient) | Clinicians should not recommend e-cigarettes for cessation; refer to FDA-approved pharmacotherapy instead |
Prognosis and Natural History
- ▸Untreated quit rates are low; proactive outreach yields NNT=10.
- ▸In schizophrenia, NNT=6 for personalized intervention.
Without assistance, most smokers cycle through multiple quit attempts. Spontaneous 6-month abstinence rates range from 0.5% (very brief advice) to 18.8% (usual care in primary care) [53]A1b[71]A1b. Proactive outreach to low-SES smokers achieves 17.8% vs 8.1% (OR 2.5, NNT=10) [47]A1b. Chatbot intervention: 26% vs 18.8% (OR 1.52, NNT=14) [53]A1b. Brief community outreach in India: 2.6% vs 0.5% (RR 5.32, NNT=48) [71]A1b. In schizophrenia, personalized intervention: 28% vs 10.8% (NNT=6) [10]A1b. For people with HIV, combination NRT plus counseling: 15% vs 10% (aOR 1.47, NNT=20, not significant) [26]A1b. Post-discharge sustained care improved self-reported abstinence at 3 months (37% vs 30%) but not biochemically confirmed at 6 months [63]A1b. Dental professional interventions: RR 1.86 for single session [2]A1a. For young people, group counseling effective (RR 1.35) [54]A1a. Pearl: The absolute benefit of cessation interventions is modest, typically 5% to 20% absolute increase in quit rates, but the NNTs are as low as 6 in high-risk populations (e.g., schizophrenia). For the generalist, the most efficient strategy is to offer proactive outreach (NNT=10) [47]A1b and use group counseling for young smokers (RR 1.35) [54]A1a.
| Intervention | Population | Control quit rate | Intervention quit rate | Absolute difference | NNT (95% CI) | Source |
|---|---|---|---|---|---|---|
| Proactive outreach + NRT | Low-SES adults | 8.1% | 17.8% | 9.7% | 10 | [47]A1b |
| Chatbot (Dejal@bot) | Primary care smokers | 18.8% | 26.0% | 7.2% | 14 | [53]A1b |
| Brief community outreach | LMIC community | 0.5% | 2.6% | 2.1% | 48 | [71]A1b |
| Personalized package | Schizophrenia | 10.8% | 28.0% | 17.2% | 6 | [10]A1b |
| c-NRT + counseling | HIV (South Africa) | 10.0% | 15.0% | 5.0% | 20 (not significant) | [26]A1b |
| Sustained Care (post-discharge) | Hospitalized smokers | 16.0% | 17.0% | 1.0% | Not significant | [63]A1b |
Special Populations and Pregnancy
- ▸Behavioral counseling is first-line for pregnancy; pharmacotherapy not recommended.
- ▸Partner support and mental health screening improve outcomes.
Pregnancy: USPSTF recommends behavioral interventions (Grade A). Behavioral counseling increases cessation in late pregnancy (RR 1.35) [46]A1a. Evidence for pharmacotherapy (NRT) is insufficient (pooled RR 1.11) [46]A1a. Women with pre-pregnancy depression/anxiety are more likely to smoke prenatally (aPR 1.7) and less likely to quit (aPR 0.86) [73]C4. Tobacco smoking is associated with postpartum depression (aOR 1.33-2.35) [36]C4. Partner support improves quitting (OR 1.48) [74]C4. Higher education strongly associated with cessation (OR 14.3) [74]C4. In low- and middle-income countries, cessation during pregnancy is not prioritized [75]D5. Pediatrics (adolescents): USPSTF evidence insufficient; no pharmacotherapy trials. Group counseling is effective (RR 1.35) [54]A1a. Elderly: no specific data; apply general recommendations with caution for comorbidities. Immunocompromised: no evidence; use general principles. Pearl: For pregnant persons, behavioral counseling is the first-line intervention; pharmacotherapy should be deferred due to insufficient evidence of benefit and unknown harms [45]A1c[46]A1a. Partner support and mental health screening are critical adjuncts.
Prevention, Screening and Health Maintenance
- ▸Universal screening at every encounter is Grade A.
- ▸Proactive outreach to low-SES smokers yields NNT=10.
USPSTF Grade A: ask all adults about tobacco use and provide cessation interventions; ask all pregnant women and provide pregnancy-tailored counseling [60]A1c. Screen at every encounter. EHR can identify smokers for proactive outreach. Proactive strategy for low-SES smokers: telephone counseling + free NRT for 6 weeks + referrals gave 17.8% vs 8.1% quit rate (OR 2.5, NNT=10) [47]A1b. Primary prevention: group counseling for youth (RR 1.35) [54]A1a; motivational enhancement (RR 1.60) [12]A1a; TTM-based interventions (pooled RR 1.56) [12]A1a. Secondary prevention: cessation at cancer diagnosis improves survival (15-29% reduction in lung cancer mortality) [28]D5. Continued use post-diagnosis is high (74% in Indian cancer patients) [17]B2a. Interventions for non-respiratory cancers: OR 1.24 [49]A1a. Training health professional students in 5A's increases counseling skills (SMD 1.03) and quit rates (OR 2.02, 78 more quitters per 1000) [76]A1a. Pearl: The single most effective population-level strategy is universal screening at every clinical encounter followed by a brief intervention, the USPSTF Grade A recommendation is supported by an NNT of 10 for proactive outreach in low-SES populations [47]A1b[60]A1c.
| Population | Recommendation | Grade | Source |
|---|---|---|---|
| All adults | Ask about tobacco use; provide cessation interventions | A | USPSTF 2009 [60]A1c |
| Pregnant women | Ask about tobacco use; provide augmented, pregnancy-tailored counseling | A | USPSTF 2009 [60]A1c |
| Low-SES adult smokers | Proactive EHR-based outreach with counseling, NRT, and community referrals | , | Haas et al. 2015 [47]A1b |
| Hospitalized smokers | Automated IVR calls + free medication post-discharge | , | Rigotti et al. 2016 [63]A1b |
| Adolescents (aged <20) | Group counseling | , | Fanshawe et al. 2017 [54]A1a |
| Cancer patients (non-respiratory) | Combined behavioral + pharmacotherapy | , | Dhumal et al. 2024 [49]A1a |
References
- [1]
Carr AB, Ebbert J. “Interventions for tobacco cessation in the dental setting.” The Cochrane database of systematic reviews (2012). PMID: 22696348 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Long-term and Definitive Management, Prognosis and Natural History - [2]
Holliday R, Hong B, McColl E et al.. “Interventions for tobacco cessation delivered by dental professionals.” The Cochrane database of systematic reviews (2021). PMID: 33605440 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Long-term and Definitive Management, Prognosis and Natural History - [3]
Grimshaw GM, Stanton A. “Tobacco cessation interventions for young people.” The Cochrane database of systematic reviews (2006). PMID: 17054164 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance - [4]
Apollonio D, Philipps R, Bero L. “Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders.” The Cochrane database of systematic reviews (2016). PMID: 27878808 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Diagnosis and Workup, Long-term and Definitive Management - [5]
Vijayaraghavan M, Elser H, Frazer K et al.. “Interventions to reduce tobacco use in people experiencing homelessness.” The Cochrane database of systematic reviews (2020). PMID: 33284989 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Severity, Staging and Risk Stratification - [6]
Shen X, Bachyrycz A, Anderson JR et al.. “Quitting patterns and predictors of success among participants in a tobacco cessation program provided by pharmacists in New Mexico.” Journal of managed care & specialty pharmacy (2014). PMID: 24856596 ↗
L4OTHERCited in: Definition, Classification and Nomenclature - [7]
Chiseya LS, Myers B. “"Cigarettes led me back to smoking tik": lived experience perspectives on tobacco use during substance use treatment and recovery in South Africa.” Addiction science & clinical practice (2026). PMID: 41821057 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [8]
Martinez Leal I, Taing M, Correa-Fernández V et al.. “Addressing Smoking Cessation among Women in Substance Use Treatment: A Qualitative Approach to Guiding Tailored Interventions.” International journal of environmental research and public health (2021). PMID: 34072064 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [9]
Shelley D, Armstrong-Hough M, Nguyen T et al.. “Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial.” The Lancet. Global health (2026). PMID: 41713442 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Prognosis and Natural History - [10]
Rajalu BM, Jayarajan D, Muliyala KP et al.. “Effectiveness of personalized tobacco cessation intervention package among patients with schizophrenia and related psychotic disorders - A two-group experimental study.” Asian journal of psychiatry (2023). PMID: 36652840 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History - [11]
Awaisu A, Nik Mohamed MH, Mohamad Noordin N et al.. “The SCIDOTS Project: evidence of benefits of an integrated tobacco cessation intervention in tuberculosis care on treatment outcomes.” Substance abuse treatment, prevention, and policy (2011). PMID: 21943384 ↗
L2RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup - [12]
Stanton A, Grimshaw G. “Tobacco cessation interventions for young people.” The Cochrane database of systematic reviews (2013). PMID: 23975659 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance - [13]
Wipfli H, Arinaitwe J, Goma F et al.. “A phone-based tobacco use cessation program for people living with HIV in Uganda and Zambia: study protocol for a randomized controlled trial.” Addiction science & clinical practice (2024). PMID: 38243301 ↗
L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management - [14]
Rasmussen M, Larsson M, Gilljam H et al.. “Effectiveness of tobacco cessation interventions for different groups of tobacco users in Sweden: a study protocol for a national prospective cohort study.” BMJ open (2022). PMID: 35078840 ↗
L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management - [15]
Mahabee-Gittens EM, Gordon J. “Acceptability of tobacco cessation interventions in the pediatric emergency department.” Pediatric emergency care (2008). PMID: 18431218 ↗
L4RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management - [16]
Heshmati J, Abraham A, Miles J et al.. “Tobacco cessation strategies in military personnel: A meta-analysis of randomized trials.” Preventive medicine reports (2025). PMID: 41477657 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [17]
Rajan V, Muralikrishnan S, Nagappa B et al.. “Continued tobacco use beyond cancer diagnosis in India - A systematic review and meta-analysis.” Journal of cancer policy (2025). PMID: 40484231 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Prevention, Screening and Health Maintenance - [18]
Han B, Aung TW, Volkow ND et al.. “Tobacco Use, Nicotine Dependence, and Cessation Methods in US Adults With Psychosis.” JAMA network open (2023). PMID: 36976558 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis and Workup, Severity, Staging and Risk Stratification - [19]
Reed D, Danberry K. “Smokeless Tobacco Cessation in an Emergency Room in Rural West Virginia.” Frontiers in public health (2022). PMID: 35462820 ↗
L4OTHERCited in: Clinical Presentation, Acute Management - [20]
Irwin KE, Steffens EB, Yoon Y et al.. “Lung Cancer Screening Eligibility, Risk Perceptions, and Clinician Delivery of Tobacco Cessation Among Patients With Schizophrenia.” Psychiatric services (Washington, D.C.) (2019). PMID: 31357921 ↗
L4OTHERCited in: Clinical Presentation - [21]
Rodríguez-Esquivel D, Cooper TV, Blow J et al.. “Characteristics associated with smoking in a Hispanic sample.” Addictive behaviors (2009). PMID: 19394148 ↗
L4OTHERCited in: Clinical Presentation, Complications - [22]
Wichman ML, Wall DM, Garcia Mota SS et al.. “Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community.” Clinical and translational science (2025). PMID: 40078094 ↗
L4OTHERCited in: Clinical Presentation - [23]
Rogova A, Reitzel LR, Lowenstein LM et al.. “Implementation of a hybrid lung health program for Northeast Texas: study protocol.” Implementation science communications (2026). PMID: 41709306 ↗
L5OTHERCited in: Clinical Presentation - [24]
Thomas T, Pradeep Raj J, Pinheiro T et al.. “Effectiveness of tobacco cessation interventions and risk factors for tobacco-use relapse: A cohort study.” The National medical journal of India (2026). PMID: 42240507 ↗
L4COHORTCited in: Clinical Presentation - [25]
Rigotti NA, Chang Y, Rosenfeld LC et al.. “Interactive Voice Response Calls to Promote Smoking Cessation after Hospital Discharge: Pooled Analysis of Two Randomized Clinical Trials.” Journal of general internal medicine (2017). PMID: 28616847 ↗
L2RCTCited in: Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Prevention, Screening and Health Maintenance - [26]
Elf JL, Lebina L, Motlhaoleng K et al.. “A randomized trial for combination nicotine replacement therapy for smoking cessation among people with HIV in a low-resourced setting.” AIDS (London, England) (2024). PMID: 39693492 ↗
L1RCTCited in: Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History, Prevention, Screening and Health Maintenance - [27]
Carr AB, Ebbert JO. “Interventions for tobacco cessation in the dental setting.” The Cochrane database of systematic reviews (2006). PMID: 16437517 ↗
L1SR_OBSCited in: Diagnosis and Workup, Long-term and Definitive Management - [28]
Petrelli F, Ghidini A, Rossitto M et al.. “An umbrella review of meta-analyses on smoking cessation and cancer survival: a brief report.” Lung cancer (Amsterdam, Netherlands) (2025). PMID: 41005236 ↗
L5SR_OBSCited in: Diagnosis and Workup, Prevention, Screening and Health Maintenance - [29]
Carr AB, Ebbert JO. “Interventions for tobacco cessation in the dental setting. A systematic review.” Community dental health (2007). PMID: 17615820 ↗
L1SR_OBSCited in: Diagnosis and Workup - [30]
Yu LQ, Amato MS, Papandonatos GD et al.. “Predicting Early Dropout in a Digital Tobacco Cessation Intervention: Replication and Extension Study.” Journal of medical Internet research (2024). PMID: 39602788 ↗
L3OTHERCited in: Diagnosis and Workup - [31]
Thielking AM, Fitzmaurice KP, Sewpaul R et al.. “Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study.” Journal of the International AIDS Society (2024). PMID: 38924347 ↗
L2OTHERCited in: Diagnosis and Workup - [32]
Crosland P, Scollo M, White SL et al.. “Cost-effectiveness and productivity impacts of call-back telephone counselling for smoking cessation.” Public health research & practice (2023). PMID: 37287193 ↗
L2OTHERCited in: Diagnosis and Workup - [33]
Jeyashree K, Kathirvel S, Shewade HD et al.. “Smoking cessation interventions for pulmonary tuberculosis treatment outcomes.” The Cochrane database of systematic reviews (2016). PMID: 26777994 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term and Definitive Management - [34]
Mullen KA, Garg A, Gagnon F et al.. “The INITIATE trial protocol: a randomized controlled trial testing the effectiveness of a "quit card" intervention on long-term abstinence among tobacco smokers presenting to the emergency department.” Trials (2021). PMID: 34688291 ↗
L5TRIAL_NONRANDOMCited in: Severity, Staging and Risk Stratification, Acute Management - [35]
Qin A, Wang M, Qi Y et al.. “Is tobacco dependence a moderator of psychiatric symptom severity and caregiver abuse in rural families of patients with severe mental disorders?” Psychological medicine (2025). PMID: 41310965 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification - [36]
Beckodro CK, Conteh V, Nsitou B et al.. “Tobacco smoking and postpartum depression symptoms in the Pregnancy Risk Assessment and Monitoring System (PRAMS) study.” Journal of affective disorders (2025). PMID: 40288456 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification, Special Populations and Pregnancy - [37]
Ripley GH, Carlin VE, Deyo AG et al.. “Severity of Disability-Related Functional Difficulties and Tobacco Use Patterns in a National Sample of U.S. Veterans.” Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco (2026). PMID: 42372058 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification - [38]
Melzer AC, Feemster LC, Crothers K et al.. “Respiratory and Bronchitic Symptoms Predict Intention to Quit Smoking among Current Smokers with, and at Risk for, Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2016). PMID: 27268422 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification - [39]
Walters EL, Reibling ET, Wilber ST et al.. “Emergency department provider preferences related to clinical practice guidelines for tobacco cessation: a multicenter survey.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2014). PMID: 25112653 ↗
L4GUIDELINECited in: Acute Management, Generalist Reasoning under Diagnostic Uncertainty, Point-of-Care Scores & Referral Thresholds - [40]
Christiansen BA, Brooks M, Keller PA et al.. “Closing tobacco-related disparities: Using community organizations to increase consumer demand.” American journal of preventive medicine (2010). PMID: 20176314 ↗
L1RCTCited in: Acute Management - [41]
Plever S, Kisely SR, Bonevski B et al.. “Interventions for smoking cessation in inpatient psychiatry settings.” The Cochrane database of systematic reviews (2026). PMID: 42389948 ↗
L1SR_OBSCited in: Acute Management, Long-term and Definitive Management - [42]
Pelletier JH, Strout TD, Baumann MR. “A systematic review of smoking cessation interventions in the emergency setting.” The American journal of emergency medicine (2014). PMID: 24768666 ↗
L5SR_OBSCited in: Acute Management, Generalist Reasoning under Diagnostic Uncertainty, Point-of-Care Scores & Referral Thresholds - [43]
Russell AM, Colditz JB, Barry AE et al.. “Analyzing Twitter Chatter About Tobacco Use Within Intoxication-related Contexts of Alcohol Use: "Can Someone Tell Me Why Nicotine is So Fire When You're Drunk?".” Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco (2022). PMID: 34562100 ↗
L5OTHERCited in: Acute Management - [44]
Mullen KA, Manuel DG, Hawken SJ et al.. “Effectiveness of a hospital-initiated smoking cessation programme: 2-year health and healthcare outcomes.” Tobacco control (2016). PMID: 27225016 ↗
L2OTHERCited in: Acute Management - [45]
Krist AH, Davidson KW, Mangione CM et al.. “Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement.” JAMA (2021). PMID: 33464343 ↗
L1GUIDELINECited in: Long-term and Definitive Management, History and Evolution of Treatment, Complications, Special Populations and Pregnancy - [46]
Patnode CD, Henderson JT, Coppola EL et al.. “Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2021). PMID: 33464342 ↗
L1SR_OBSCited in: Long-term and Definitive Management, Special Populations and Pregnancy - [47]
Haas JS, Linder JA, Park ER et al.. “Proactive tobacco cessation outreach to smokers of low socioeconomic status: a randomized clinical trial.” JAMA internal medicine (2015). PMID: 25506771 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History, Prevention, Screening and Health Maintenance - [48]
Duffy SA, Karvonen-Gutierrez CA, Ewing LA et al.. “Implementation of the Tobacco Tactics program in the Department of Veterans Affairs.” Journal of general internal medicine (2010). PMID: 20077145 ↗
L2RCTCited in: Long-term and Definitive Management - [49]
Dhumal T, Kelly KM, Khadka S et al.. “Tobacco Cessation Interventions in Non-Respiratory Cancers: A Systematic Review With Meta-analysis of Randomized Controlled Trials.” Annals of behavioral medicine : a publication of the Society of Behavioral Medicine (2024). PMID: 38985846 ↗
L1SR_MA_RCTCited in: Long-term and Definitive Management, Prevention, Screening and Health Maintenance - [50]
Leutwyler H, Hubbard E, Bussell T et al.. “A Pilot Randomized Controlled Trial of a Multicomponent Smoking Cessation Intervention for Adults with Serious Mental Illness.” Games for health journal (2024). PMID: 39587943 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Prevention, Screening and Health Maintenance - [51]
Wang Y, Peng P, Wu Z et al.. “Boosting Smoking Cessation Intervention Utilization in Chinese Health Care Providers: A Randomized Controlled Trial of the "WeChat WeQuit" Medical Education Program.” Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco (2024). PMID: 39083005 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History - [52]
Hartmann-Boyce J, Lindson N. “Assessing and minimizing risk of bias in randomized controlled trials of tobacco cessation interventions: Guidance from the Cochrane Tobacco Addiction Group.” Addiction (Abingdon, England) (2023). PMID: 37132075 ↗
L5RCTCited in: Long-term and Definitive Management - [53]
Olano-Espinosa E, Avila-Tomas JF, Minue-Lorenzo C et al.. “Effectiveness of a Conversational Chatbot (Dejal@bot) for the Adult Population to Quit Smoking: Pragmatic, Multicenter, Controlled, Randomized Clinical Trial in Primary Care.” JMIR mHealth and uHealth (2022). PMID: 35759328 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History - [54]
Fanshawe TR, Halliwell W, Lindson N et al.. “Tobacco cessation interventions for young people.” The Cochrane database of systematic reviews (2017). PMID: 29148565 ↗
L1SR_OBSCited in: Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance - [55]
Maziak W, Jawad M, Jawad S et al.. “Interventions for waterpipe smoking cessation.” The Cochrane database of systematic reviews (2015). PMID: 26228266 ↗
L1SR_OBSCited in: Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance - [56]
Asfar T, Livingstone-Banks J, Ward KD et al.. “Interventions for waterpipe smoking cessation.” The Cochrane database of systematic reviews (2023). PMID: 37286509 ↗
L1SR_OBSCited in: Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance - [57]
Maziak W, Ward KD, Eissenberg T. “Interventions for waterpipe smoking cessation.” The Cochrane database of systematic reviews (2007). PMID: 17943865 ↗
L1SR_OBSCited in: Long-term and Definitive Management, Prognosis and Natural History - [58]
Rasool S, Dobbie F, Khan Z et al.. “Process evaluation of a pragmatic feasibility trial on smokeless tobacco cessation intervention delivered in dental hospitals.” BMC public health (2024). PMID: 38755594 ↗
L4TRIAL_NONRANDOMCited in: Long-term and Definitive Management - [59]
Pradhan PMS, Funnell MP, Sagtani RA et al.. “Effectiveness of tobacco cessation interventions delivered in clinical settings in South Asia: a systematic review and meta-analysis.” Global health action (2026). PMID: 42394572 ↗
L1SR_OBSCited in: Long-term and Definitive Management, Prevention, Screening and Health Maintenance - [60]
. “Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement.” Annals of internal medicine (2009). PMID: 19380855 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Special Populations and Pregnancy, Prevention, Screening and Health Maintenance - [61]
. “A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives.” JAMA (2000). PMID: 10866874 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [62]
Lichtenstein E, Hollis JF, Severson HH et al.. “Tobacco cessation interventions in health care settings: rationale, model, outcomes.” Addictive behaviors (1996). PMID: 8904937 ↗
L5RCTCited in: History and Evolution of Treatment - [63]
Rigotti NA, Tindle HA, Regan S et al.. “A Post-Discharge Smoking-Cessation Intervention for Hospital Patients: Helping Hand 2 Randomized Clinical Trial.” American journal of preventive medicine (2016). PMID: 27647060 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Prevention, Screening and Health Maintenance - [64]
Yuan NP, Castañeda H, Nichter M et al.. “Lay health influencers: how they tailor brief tobacco cessation interventions.” Health education & behavior : the official publication of the Society for Public Health Education (2011). PMID: 21986244 ↗
L4RCTCited in: History and Evolution of Treatment - [65]
King BA, Dube SR, Babb SD et al.. “Patient-reported recall of smoking cessation interventions from a health professional.” Preventive medicine (2013). PMID: 23872172 ↗
L4OTHERCited in: Generalist Reasoning under Diagnostic Uncertainty, Point-of-Care Scores & Referral Thresholds - [66]
Harrogate S, Barnes J, Thomas K et al.. “Peri-operative tobacco cessation interventions: a systematic review and meta-analysis.” Anaesthesia (2023). PMID: 37656151 ↗
L1SR_OBSCited in: Complications - [67]
Harrogate SR, Barnes JD, Gupta S et al.. “Protocol for a systematic review and meta-analysis of tobacco-cessation interventions delivered perioperatively.” BMJ open (2023). PMID: 37714672 ↗
L5SR_OBSCited in: Complications - [68]
Battalio SL, Pfammatter AF, Kershaw KN et al.. “Mobile Health Tobacco Cessation Interventions to Promote Health Equity: Current Perspectives.” Frontiers in digital health (2022). PMID: 35847415 ↗
L5OTHERCited in: Complications - [69]
Hwong AR, Schmittdiel J, Schillinger D et al.. “Smoking cessation treatment for individuals with comorbid diabetes and serious mental illness in an integrated health care delivery system.” Addictive behaviors (2020). PMID: 33129613 ↗
L3OTHERCited in: Complications - [70]
Veldheer S, Yingst J, Rogers AM et al.. “Completion rates in a preoperative surgical weight loss program by tobacco use status.” Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (2017). PMID: 28392255 ↗
L4OTHERCited in: Complications - [71]
Sarkar BK, West R, Arora M et al.. “Effectiveness of a brief community outreach tobacco cessation intervention in India: a cluster-randomised controlled trial (the BABEX Trial).” Thorax (2016). PMID: 27708113 ↗
L1RCTCited in: Prognosis and Natural History - [72]
Jackson MA, Baker AL, McCarter KL et al.. “Interventions for pregnant women who use tobacco and other substances: a systematic review protocol.” BMJ open (2019). PMID: 31719091 ↗
L5SR_OBSCited in: Special Populations and Pregnancy - [73]
Tong VT, Farr SL, Bombard J et al.. “Smoking Before and During Pregnancy Among Women Reporting Depression or Anxiety.” Obstetrics and gynecology (2016). PMID: 27500342 ↗
L4OTHERCited in: Special Populations and Pregnancy - [74]
Dascăl MD, Meghea CI, Blaga OM. “A Cross-Section Study of Relationship Characteristics and Smoking Cessation During Pregnancy in a Sample of Romanian Pregnant Women.” Maternal and child health journal (2020). PMID: 32048171 ↗
L4OTHERCited in: Special Populations and Pregnancy - [75]
Saygın Avşar T, Jackson L, McLeod H. “Potential for health economics to influence policies on tobacco use during pregnancy in low-income and middle-income countries: a qualitative case study.” BMJ open (2021). PMID: 34880008 ↗
L5OTHERCited in: Special Populations and Pregnancy - [76]
Hyndman K, Thomas RE, Schira HR et al.. “The Effectiveness of Tobacco Dependence Education in Health Professional Students' Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” International journal of environmental research and public health (2019). PMID: 31661922 ↗
L1SR_MA_RCTCited in: Prevention, Screening and Health Maintenance - [77]
Fernandez ME, Schlechter CR, Del Fiol G et al.. “QuitSMART Utah: an implementation study protocol for a cluster-randomized, multi-level Sequential Multiple Assignment Randomized Trial to increase Reach and Impact of tobacco cessation treatment in Community Health Centers.” Implementation science : IS (2020). PMID: 32000812 ↗
L5TRIAL_NONRANDOMCited in: Prevention, Screening and Health Maintenance